Mirum Pharmaceuticals’ latest findings: Game-changing liver treatment delivers lasting relief
Get Email Alerts and Follow Us: On May 18, 2024, Mirum Pharmaceuticals revealed important findings at the 56th ESPGHAN Annual Meeting in Milan, showcasing the efficacy of LIVMARLI® (maralixibat) in treating Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Clinical and real-world data indicate significant improvements in patients’ liver health and reduction in pruritus…